Sunday, September 25, 2011

IND-SWIFT LABORATORIES HOLDS DMF FOR QUETIAPINE AND ATORVASTATIN

Ind-Swift Laboratories limited (ISLL) holds DMF for the two best in class products - Lipitor and Seroquel.  The incremental worldwide revenue that ISLL would generate from just these two DMF's would be close to an incremental 300 Cr and the EBITDA would be close to 150 Cr. Hence over the next two years ISLL profits should more than double from current levels.   Besides Lipitor and Seroquel, Ind-swift holds DMF for another 20 products, most of which are mega blockbusters.